#36 Maagzuurremmers, stoppen of doorgaan?

Nederland ken ruim 2 miljoen gebruikers van maagzuurremmers, is dat niet heel veel? Zijn er geen mensen die kunnen stoppen met maagzuurremmers en als je wilt stoppen, kan je dat zomaar doen? Hoe bouw je maagzuurremmers het beste af? Welke maagzuurremmers zijn er eigenlijk? In deze apotekerspodcast wordt dit allemaal uitgelegd.Gebruikte literatuur:1.  Islam MdM, Poly TN, Walther BA, Dubey NK, Ningrum DNA, Shabbir S-A, et al. Adverse outcomes of long-term use of proton pump inhibitors. Eur J Gastroen Hepat. 2018;30(12):1395–405.2.  Gomm W, Holt K von, Thomé F, Broich K, Maier W, Fink A, et al. Association of Proton Pump Inhibitors With Risk of Dementia. JAMA Neurology. 2016 Apr 1;73(4):410–7.3.  Lyu B, Hansen KE, Jorgenson MR, Astor BC. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients. American Journal of Nephrology [Internet]. 2020 Jun 24;51(6):433–41. Available from: https://www-karger-com.proxy.library.uu.nl/Article/Pdf/5074704.  Ben‐Eltriki M, Green CJ, Maclure M, Musini V, Bassett KL, Wright JM. Do proton pump inhibitors increase mortality? A systematic review and in‐depth analysis of the evidence. Pharmacol Res Perspectives. 2020;8(5):e00651.5.  Kuller LH. Do Proton Pump Inhibitors Increase the Risk of Dementia? JAMA Neurology. 2016 Apr;73(4):379–81.6.  Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. Bmj. 2019;365:l1580.7.  Willems RPJ, Dijk K van, Ket JCF, Vandenbroucke-Grauls CMJE. Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms. Jama Intern Med. 2020;180(4):561–71.8.  Willems RPJ, Dijk K van, Ket JCF, Vandenbroucke-Grauls CMJE. Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms. JAMA Internal Medicine. 2020 Apr 1;180(4):561–11.9.  Ford CD, Lopansri BK, Haydoura S, Snow G, Dascomb KK, Asch J, et al. Frequency, Risk Factors, and Outcomes of Vancomycin-Resistant EnterococcusColonization and Infection in Patients with Newly Diagnosed Acute Leukemia: Different Patterns in Patients with Acute Myelogenous and Acute Lymphoblastic Leukemia. Infection Control & Hospital Epidemiology. 2015 Jan 5;36(1):47–53.10.  Singh-Franco D, Mastropietro DR, Metzner M, Dressler MD, Fares A, Johnson M, et al. Impact of pharmacy-supported interventions on proportion of patients receiving non-indicated acid suppressive therapy upon discharge: A systematic review and meta-analysis. Plos One. 2020;15(12):e0243134.11.  D’Silva KM, Mehta R, Mitchell M, Lee TC, Singhal V, Wilson MG, et al. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: A systematic review & meta-analysis. Clin Microbiol Infec. 2021;27(5):697–703.12.  Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. Jama Intern Med. 2016;176(2):238–46.13.  Srinutta T, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, et al. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine. 2019;98(44):e17788.14.  Orelio CC, Heus P, Dieren JJK, Spijker R, Munster BC van, Hooft L. Reducing Inappropriate Proton Pump Inhibitors Use for Stress Ulcer Prophylaxis in Hospitalized Patients: Systematic Review of De-Implementation Studies. J Gen Intern Med. 2021;1–9.15.  Tran‐Duy A, Connell NJ, Vanmolkot FH, Souverein PC, Wit NJ, Stehouwer CDA, et al. Use of proton pump inhibitors and risk of iron deficiency: a population‐based case–control&